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Abstract Cytokines, involved in the T-helper 1 system,
play a role in the regulation of hepatitis B virus (HBV)
clearance and the immune response to HBV antigens during
natural infection or planned vaccination. Our aim was to
examine whether the polymorphic variants of IL-12 are
equally associated with development of antibodies to HBV
surface antigen (anti-HBs) in hemodialysis (HD) patients in
the case of HBV vaccination or HBV infection. The IL-12A
rs568408 and IL-12B rs3212227 polymorphisms were
analyzed in relation to anti-HBs development in 602 HD
patients with negative antibodies to HBV core antigen (anti-
HBc) who were hepatitis B vaccinated (group I) as well as
in 237 anti-HBc positive HD patients who were infected
with HBV in the past (group II). In group I, 199 patients did
not develop an anti-HBs titre [10 IU/L (subgroup Ia),
whereas in group II, 55 patients did not develop an anti-HBs
titre [10 IU/L (subgroup IIa). Patients of groups I and II
that developed an anti-HBs [10 IU/L were included into
subgroups Ib and IIb, respectively. In hepatitis B vaccinated
HD patients, development of a protective anti-HBs titre was
positively associated with vintage of renal replacement
therapy (RRT), chronic glomerulonephritis as a cause of
RRT, and GA rs 568408 IL-12A (OR 1.6, 95 % CI 1.0–2.5,
P = 0.035), but a frequency distribution of this genotype
between responders and non-responders was not significant
when the Bonferroni correction was applied. In HBV
infected HD patients, anti-HBs development was positively
associated with AC rs3212227 IL-12B (OR 8.0, 95 % CI
2.6–24.9, P \ 0.001), whereas HBsAg positivity, AA
rs3212227 IL-12B (OR 0.3, 95 % CI 0.1–0.7, P = 0.007),
and CC rs3212227 IL-12B (OR 0.1, 95 % CI 0.03–0.6,
P = 0.011) were negative predictors of positive anti-HBs
phenotype. When the Bonferroni correction was applied, if
appropriate, these associations remained significant. In HD
patients, the studied IL-12 polymorphic variants seem to be
associated with the anti-HBs phenotype (a) with borderline
significance for IL-12A in hepatitis B vaccinated patients,
and (b) significantly for IL-12B in patients who underwent
natural HBV infection.
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Introduction
Antibodies to the surface antigen of the hepatitis B virus
(anti-HBs) are specific neutralizing antibodies indicative of
either an immune response triggered as a result of having
received a vaccine containing the surface antigen of the
hepatitis B virus (HBsAg) or active immunity to the hep-
atitis B virus (HBV) as a result of prior infection with HBV
having HBsAg in its structure. Anti-HBs in the blood-
stream may also result from passive immunity created by
injection of hepatitis B immunoglobulin for post-exposure
prophylaxis.
According to the current recommendations, protection
of hemodialysis (HD) patients against HBV infection
should include hepatitis B vaccination using licensed
hepatitis B vaccines given at 0, 1, 2 and 6 months in the
dose of 40 lg each administered by the intramuscular route
at one site. Patients who did not respond to the primary
vaccine series should be revaccinated with three additional
doses and retested for response [1]. The development of
this advanced vaccination strategy still does not elicit the
adequate anti-HBs response in 20 % HD vaccinees [2].
Therefore, a substantial number of HD patients is not
adequately protected against HBV infection.
Natural HBV transmission to the human body leads to
the appearance of specific seromarkers, among them
HBsAg, antibodies to HBV core antigen (anti-HBc), and
anti-HBs. The development of anti-HBs used to be asso-
ciated with the disappearance of HBsAg. Anti-HBc are
established markers of current (in IgM class) or past (in
IgG class) HBV infection. If anti-HBs do not appear during
the HBV infection, it results either in HBsAg carrier status,
which is associated with detectable HBV deoxyribonucleic
acid (DNA) in about 65 % of infected HD patients [3, 4],
or in the occurrence of isolated anti-HBc positivity (anti-
HBc positive individuals are both HBsAg and anti-HBs
negative), which in HD patients may be associated with
detectable HBV DNA [5]. HBV replication may contribute
to morbidity and mortality related to HBV-associated dis-
eases [6–8]. Ineffective hepatitis B vaccination is predic-
tive for the prevalence and incidence of both HBsAg [9]
and anti-HBc [10, 11] positivity.
Interleukin (IL)-12 is a heterodimeric proinflammatory
cytokine composed of a 35 kDa light chain and a 40 kDa
heavy chain. IL-12 plays a key role in the regulation of the
immune response to HBV antigens during spontaneous
infection [12–14] or planned vaccination [15, 16]. IL-12 is
a member of the cytokine network, which includes pro- and
anti-inflammatory bioactive peptides. This network may be
influenced by multiple factors, such as blood transfusions
[17], stress [18], iron status [19] and many others, resulting
in changes in serum levels of interleukins. The concen-
trations of these cytokines, among them IL-12, reflect
actual somatic and behavioral status, whereas genotypes
are not influenced by internal and external signals.
The light (35 kDa) and heavy (40 kDa) chains of IL-12
are encoded by the IL12A and IL12B genes, respectively.
The 30untranslated regions (UTRs) influence the amount of
translated protein [20], therefore the single nucleotide
polymorphisms (SNPs) IL12A G[A (rs568408) and IL12B
A[C (rs3212227), located in the 30 UTR, are suspected in
the modulation of IL-12 levels [21]. Polymorphisms and
haplotypes in IL-12B have already been directly associated
with IL-12 production in previous studies [22, 23]. More-
over, the number of polymorphisms located in IL-12B is
limited and these SNPs display significant linkage dis-
equilibrium [22]. Therefore, polymorphisms in the 30 UTR
region of IL12A (rs568408) and IL12B (rs3212227),
influencing IL-12 levels, might also affect the immune
response to HBV antigens.
A recent study [24] has shown no association with HBV
persistence and IL-12A, whereas the IL-12B promoter S
allele was associated with non-responsiveness to HBV
vaccination [25]. Our recent studies have shown that
polymorphic variants of IL-18 individually or jointly with
polymorphic variants of IL-12A or IL-12B are associated
with the development of anti-HBs in HD patients [26, 27].
It could not be distinguished from these studies [26, 27],
whether there is any difference in the association between
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anti-HBs development and the examined polymorphic
variants when anti-HBs are generated in response to HBV
transmission after HBV clearance or when the protective
immune humoral response is triggered by the vaccine
selectively containing the S protein of HBsAg. This task
seems to be especially meaningful in light of an earlier
study showing that some inbred strains of mice that are
unresponsive to protein S of HBsAg do produce anti-HBs
when immunized with a larger surface viral protein con-
taining S HBsAg and pre-S(1) [28]. Recombinant DNA
hepatitis B vaccine containing HBsAg particles harbouring
all three viral envelope polypeptides, the major S protein
and the minor Pre-S2 and Pre-S1, was shown to be more
powerful in the development of anti-HBs than did standard
recombinant vaccines containing only S the protein [29].
The aim of our study was to perform a separate analysis
of hepatitis B vaccinated and HBV infected HD patients in
relation to the polymorphic variants of IL12A G[A
(rs568408) and IL12B A[C (rs3212227) and to assess
whether in HD patients polymorphic variants of IL-12 are
equally associated with the development of anti-HBs in the
event of HBV vaccination or HBV infection.
Materials and methods
Patients and controls
Studies were carried out in 839 HD patients treated in 22
dialysis centers located in the Wielkopolska region of
Poland. Metrical age and renal replacement therapy (RRT)
vintage that are shown in the Results section are both in
regards concern to the date that blood samples were col-
lected for genotyping. HBV seromarkers (HBsAg, anti-
HBc, anti-HBs) were determined in each patient at HD
commencement. HBsAg determinations were repeated on a
mandatory basis every 6 months, total anti-HBc voluntarily
every 8–12 months. All patients were vaccinated against
HBV with recombinant DNA yeast-derived vaccines,
composed of the S protein of HBsAg (Engerix B, Glaxo-
SmithKline Biologicals, Belgium; Hepavax–Gene, BIO-
MED SA, Poland; Euvax B, LG Chemical, South Korea)
according to the rules established for HD patients [1]. An
anti-HBs titre was checked after 4–8 weeks from the last
vaccine dose. When an anti-HBs titre remained below
10 IU/L, assumed to be non-protective in vaccinated
patients [30], vaccination was repeated. The level of anti-
HBs wanes over the time after vaccination, so a blood test
for anti-HBs was repeated in all HD patients on a man-
datory basis every 6 months to determine if vaccine
booster doses were required.
Patients enrolled to the study had to fulfill the following
criteria:
• Treatment with HD due to end-stage renal disease,
• No signs and symptoms of acute infection with blood-
borne viruses within 6 months before enrollment,
• Determined panel of HBV seromarkers sufficient for a
classification of a patient to:
• HBV vaccinated group (I) without (subgroup Ia) or
with (subgroup Ib) developed anti-HBs,
• HBV infected group (II) without (subgroup IIa) or
with (subgroup IIb) developed anti-HBs,
• From patients who disclosed a genetic relationship only
one person could participate in the study,
• Provided written consent to participate in the study.
Criteria of classification of HD patients to the aforemen-
tioned groups are presented in Table 1. Only patients with
no history of acute hepatitis B and showing HBsAg and
anti-HBc negative in all tests were included into group I.
Therefore, there was no documentation that anti-HBs could
be developed due to HBV transmission prior to immuni-
zation. Patients that were never vaccinated for hepatitis B
that consistently maintained anti-HBc positivity, also
showing isolated anti-HBs positivity, were considered to
have been infected with HBV in the past (group II).
All of the available results for HBV seromarkers of each
patient were analyzed. If a patient had an anti-HBs titre
[10 IU/L in the past and further had a decline in an anti-
HBs titre \10 IU/L, s/he was considered to be constitu-
tionally able to develop anti-HBs and was included into
group Ib or IIb.
Hepatitis B vaccinated or HBV infected HD patients,
being also infected with hepatitis C virus (HCV), were
included into the study when they were established as
HBsAg responders or not responders before HCV
transmission.
Group I included 602 patients (subgroup Ia-199, sub-
group Ib-403), group II-237 patients (subgroup IIa-55,
subgroup IIb-182).
Registered blood donors, qualified for blood donation
according to the criteria of Polish Ministry of Health [31],
served as controls for HD patients. All controls (n = 240)
showed negative blood testing for HBsAg and HBV DNA
as well as for seromarkers of infection with HCV. Unfor-
tunately, the hepatitis B vaccination rate and an anti-HBs
titre were not known in these healthy individuals.
Genotype analysis for rs568408 30UTR G[A in IL-12A
and rs3212227 30 UTR A[C in IL-12B was performed in
all patients and controls.
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Laboratory methods
HBV and HCV seromarkers, as well as serum activities of
liver enzymes, were determined as previously described
[27]. All HBV or HCV positive results were the subject of
confirmation tests.
IL-12A and IL-12B genotyping
DNA was isolated from peripheral leukocytes. The IL-12A
30UTR G [ A (rs568408) polymorphism was genotyped by
high-resolution melting curve analysis (HRM); identifica-
tion of the IL-12B 30UTR A[C (rs3212227) polymorphic
variants was carried out by polymerase chain reaction-
restriction fragment length polymorphism (PCR–RFLP), as
previously described [27]. For quality control of the tested
polymorphisms, approximately 10 % of the randomly
chosen samples were re-genotyped using commercial
sequencing. We observed 99.9 % concordance between
results of PCR-RFLP analysis and sequencing.
Statistical methods
Descriptive statistics are presented as percentage for cate-
gorical variables, and median with range for continuous
variables because asymmetry of distribution was shown in
all but one (age in subgroup IIa) variable as tested by the
Shapiro–Wilk test. The prevalence of variables was
assessed by the Chi square test, the Chi square test with
Yates correction, or the V square test, as appropriate.
Continuous variables were compared using the Mann–
Whitney U-test.
Hardy–Weinberg equilibrium was tested by the Chi
square test with one degree of freedom (P \ 0.01 for sig-
nificance) to compare the observed genotype frequencies to
the expected ones. Power analysis was conducted
employing the Fisher exact test (http://biostat.mc.
vanderbilt.edu/twiki/bin/view/Main/ PowerSampleSize).
The associations between genotypes and the anti-HBs
phenotype were estimated by computing the odds ratio
(OR) and its 95 % confidence interval (95 % CI). A fre-
quency distribution of the examined genotypes was refer-
red to that of the respective homozygous wild-type
genotypes. Results of all associations were adjusted, if
possible, for parameters which significantly differentiated
the examined groups. Values of P \ 0.05 were judged to
be significant. All probabilities were two-tailed. The
P value using the Bonferroni correction for multiple testing
was calculated, if appropriate, and related to results of the
initial statistical analysis. Logistic regression analysis was
Table 1 Criteria of classification of hemodialysis patients
Parameter Group I Group II




No Yes or no
HBsAg Negative in all available results Negative or positive
Anti-HBc Negative in all available results Positive
in a patient with documented HBsAg
currently or in the past,
in a never hepatitis B vaccinated patient
with an anti-HBs titre [10 IU/L,
confirmed by two independent
laboratories using different methods of
anti-HBc determination and maintained
in consecutive determinations in a
patient without other HBV seromarkers
Hepatitis B
vaccination
Two full vaccination series (4 doubled doses of 20 lg each
given at 0–1–2–6 months) or equivalent vaccine
summarized dose (160 lg) with anti-HBs titre B 10 IU/L
after 4–8 weeks from the last vaccine dose
At least one
vaccination series
No hepatitis B vaccination
Anti-HBs Negative (B10 IU/L) in all available results Positive ([10 IU/L)







in at least one
confirmed result
anti-HBc antibodies to core antigen of hepatitis B virus, anti-HBs antibodies to surface antigen of hepatitis B virus, HBsAg surface antigen of
hepatitis B virus
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used to show variables associated with anti-HBs phenotype
concomitantly with the examined polymorphic variant. To
address the possibility of a gene–gene interaction effect
between the analyzed SNPs, a nonparametric and genetic
model-free multifactor dimensionality reduction (MDR)
approach was used [32].
Ethical issues
This study was approved by the Institutional Review Board
of Poznan´ University of Medical Sciences, Poland.
Results
Results of HBV vaccinated HD patients (subgroups Ia
and Ib)
The selected demographic, clinical and laboratory data of
vaccinated HD patients are shown in Table 2. All patients
were Caucasian.
Distribution of IL-12A and IL-12B polymorphic variants
in subgroups Ia and Ib was in agreement with Hardy–
Weinberg equilibrium. In group I, differences of genotype
frequencies were adjusted, if possible, for age, RRT vin-
tage, and diabetic nephropathy or chronic glomerulone-
phritis as causes of RRT.
In the logistic regressions that included gender, age,
RRT vintage, kidney diseases, liver enzymes, anti-HCV,
and polymorphic variants of IL-12A, there was a positive
association of anti-HBs development in response to hepa-
titis B vaccination with concurrently RRT vintage (OR 1.3,
95 % CI 1.2–1.5, P \ 0.001), chronic glomerulonephritis
(OR 2.6, 95 % CI 1.2–5.4, P = 0.012), and GA IL-12A
(OR 1.6, 95 % CI 1.0–2.5, P = 0.035); a negative associ-
ation was shown with age (OR 0.98, 95 % CI 0.97–1.0,
P = 0.018) (P \ 0.001 for the significance of this model).
Similar results were obtained if anti-HCV were replaced in
the model by HCV RNA. If a frequency distribution of the
GA rs568408 IL-12A variant was related to that of the
homozygous wild-type genotype GG rs568408 IL-12A,
patients bearing GA had a 1.6-fold higher chance to
respond to the HBV vaccine than patients having the wild-
type genotype (sample power 74 %). However, when the
Bonferroni correction was applied this result was not sig-
nificant (Table 3).
Statistical evidence for association of the IL-12A poly-
morphism with anti-HBs development in response to hep-
atitis B vaccination is summarized in Table 4.
There was no association between the IL-12B poly-
morphism and anti-HBs phenotype (Table 3).
Results of HBV infected HD patients (subgroups IIa
and IIb)
The selected demographic, clinical and laboratory data of
infected HD patients are shown in Table 5. All patients
were Caucasian.
Table 2 The selected demographic, clinical and laboratory data of vaccinated hemodialysis patients divided into subgroups
Parameter Group I (n = 602) P value for differences
between Ia and Ib
Subgroup Ia (n = 199) Subgroup Ib (n = 403)
Men, n (% of all) 103 (51.8) 228 (56.6) 0.296
Age, years 69.6 (23.8–92.5) 62.8 (18.6–91.7) <0.001
RRT duration, years 1.0 (0.03–11.6) 2.8 (0.003–26.1) <0.001
Diabetic nephropathy, n (% of all) 72 (36.2) 102 (25.3) 0.007
Chronic glomerulonephritis, n (% of all) 11 (5.5) 78 (19.4) <0.001
Hypertensive nephropathy, n (% of all) 40 (20.1) 67 (16.6) 0.308
Chronic tubulointerstitial nephritis, n (% of all) 18 (9.0) 35 (8.7) 0.880
An anti-HBs titre [10 IU/L – 403 (100 %) NA
Positive anti-HCV, n (% of all) 11 (5.5) 37 (9.2) 0.150
Positive both anti-HCV and HCV RNA
(n, % of all anti-HCV positive)
5 (45.5) 25 (67.6) 0.288
ALT (IU/L) 13 (0.6–126) 13 (2–209) 0.222
AST (IU/L) 14 (5–97) 15 (4–177) 0.309
GGT (IU/L) 30 (5–308) 25 (0–472) 0.590
Continuous variables are expressed as median and range. Significant results are indicated using bold font
ALT alanine aminotransferase, anti-HBs antibodies to surface antigen of hepatitis B virus, anti-HCV antibodies to hepatitis C virus, AST aspartate
aminotransferase, GGT gamma-glutamyltranspeptidase, HCV RNA ribonucleic acid of hepatitis C virus, NA not applicable, RRT renal
replacement therapy
Mol Biol Rep (2013) 40:6899–6911 6903
123
Distribution of IL-12A and IL-12B polymorphic variants
did not show deviation from Hardy–Weinberg equilibrium
with exception of subgroup IIa in respect to IL-12B
(P = 0.0002). Subgroup IIa also differed in IL-12B geno-
type frequencies from controls (P = 0.016), which showed
the distribution of the IL-12B genotype in concordance
with Hardy–Weinberg equilibrium and with a previously
described control Caucasian population [22].
There was no association between the IL-12A poly-
morphism and anti-HBs phenotype (Table 6).
In the best regression models that included gender, age,
RRT vintage, kidney diseases, liver enzymes, HBsAg, anti-
HCV, history of hepatitis B, and polymorphic variants of
IL-12B (P \ 0.001 for a significance of each model), there
was a positive association of anti-HBs development in
response to hepatitis B infection with the AC polymorphic
variant of IL-12B (OR 8.0, 95 % CI 2.6–24.9, P \ 0.001);
negative associations were shown with HBsAg positivity
(OR 0.02, 95 % CI 0.003–0.07, P \ 0.001) and the CC
polymorphic variant of IL-12B (OR 0.1, 95 % CI
0.03–0.06, P = 0.011). Similar results were obtained if
anti-HCV were replaced in the model by HCV RNA, and
HBsAg by HBV DNA.
In group II, results were adjusted, if possible, for HBsAg
and chronic glomerulonephritis as a cause of RRT. If a
frequency distribution of the examined polymorphisms was
related to that of the homozygous wild-type genotype and
the Bonferroni correction was applied, AC rs3212227 IL-
12B was positively associated with anti-HBs development
(sample power 99.4 %), whereas CC rs3212227 IL-12B
was predictive for negative anti-HBs phenotype (sample
power 69.5 %, Table 6).
Selected dichotomized and combined effects of the IL-
12 polymorphisms are presented in Tables 7 and 8. Com-
pared to any other genotypes, GG rs568408 IL-12A and AC
rs3212227 IL-12B were associated with positive anti-HBs
phenotype (sample power 90.8 %), whereas both GG
rs568408 IL-12A and CC rs3212227 IL-12B (sample power
74.2 %) or both AA rs568408 IL-12A and AA rs3212227
IL-12B (sample power 66.0 %) were related to the negative
anti-HBs phenotype (Table 7). When pairs of genotypes
were referred to the other selected genotype pair, patients
bearing both GG rs568408 IL-12A and CC rs3212227 IL-
Table 3 IL-12 polymorphisms
in hemodialysis non-responders
to hepatitis B vaccine (subgroup
Ia) and hemodialysis responders
to hepatitis B vaccine (subgroup
Ib) with the development of
antibodies to surface antigen of
hepatitis B virus
a Odds ratio (OR) after




glomerulonephritis as causes of
RRT




Genotype Subgroup Ia (n = 199) n (%) Subgroup Ib (n = 403) n (%) OR (95 % CI) P value
IL-12A
GG 152 (76.4) 275 (68.2) Referent
GA 40 (20.1) 115 (28.5) 1.6 (1.0–2.5)a 0.033b
AA 7 (3.5) 13 (3.2) 1.0 (0.6–1.7)a 0.984
GA/AA 47 (23.6) 128 (31.8) 1.5 (1.0–2.3)a 0.048b
AA 7 (3.5) 13 (3.2) Referent
GA/GG 192 (96.5) 390 (96.8) 1.2 (0.4–3.2)a 0.783
Allele G 344 (86.4) 665 (82.5) Referent
Allele A 54 (13.6) 141 (17.5) 1.4 (1.0–1.9) 0.096
IL-12B
AA 121 (60.8) 231 (57.3) Referent
AC 74 (37.2) 160 (39.7) 1.0 (0.7–1.5)a 0.876
CC 4 (2.0) 12 (3.0) 1.1 (0.6–2.1)a
AC/CC 78 (39.2) 172 (42.7) 1.3 (0.4–4.5)a 0.626
CC 4 (2.0) 12 (3.0) Referent
AC/AA 195 (98.0) 391 (97.0) 0.8 (0.2–2.6)a 0.660
AlleleA 319 (79.6) 622 (77.2) Referent
Allele C 82 (20.4) 184 (22.8) 1.2 (0.9–1.6) 0.387
Table 4 Statistical evidence for association of IL-12A polymorphism
with anti-HBs development in response to hepatitis B vaccination
IL-12A
polymorphism

















GG na na ns
GA 1.6, 1.0–2.5, 0.033 ns 1.6,
1.0–2.5,
0.035
AA ns ns ns
GA/AA 1.5, 1.0–2.3, 0.048 ns ns
na not applicable, ns non-significant
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12B had a near-17-times lower chance to develop anti-HBs
compared to patients having both GG rs568408 IL-12A and
AC rs3212227 IL-12B (sample power 91.9 %, Table 8).
The MDR analysis revealed a borderline statistical
significance between subgroups IIa and IIb. In this case,
the testing balanced accuracy for the analysed 2-locus
model was 0.582, cross validation consistency 100 % and
P value derived from the 1,000-fold permutation test was
0.082.
Statistical evidence for an association of the IL-12B
polymorphism with anti-HBs development in response to
hepatitis B virus infection is summarized in Table 9.
HCV infection in HD patients
HD patients with an active HCV infection were equally
distributed among individuals that developed anti-HBs and
those that did not develop anti-HBs. This was the case for
both vaccinated (Table 2) and infected (Table 5) HD
patients. The logistic regression analysis did not reveal a
significant predictive value of anti-HCV or HCV RNA for
anti-HBs development in hepatitis B vaccinated or infected
patients.
Comparison of results of HD patients that did
not develop anti-HBs despite HBV vaccination
or infection (subgroups Ia and IIa)
Comparison of the IL-12A and IL-12B polymorphic vari-
ants in subgroups Ia and IIa revealed that a higher fre-
quency of allele G rs568408 IL-12A remained associated
with non-responsiveness to hepatitis B vaccination (OR
0.5, 95 % CI 0.3–0.9, P = 0.025), whereas the negative
anti-HBs phenotype after HBV transmission remained
associated with a higher frequency of CC rs3212227 IL-
12B (adjusted OR 4.6, 95 % CI 1.0–21.1, P = 0.047) and
lower frequencies of AC (adjusted OR 0.4, 95 % CI
0.2–1.0, P = 0.039) and AC/AA (adjusted OR 0.2, 95 %
CI 0.05–1.0, P = 0.047) compared to any other examined
genotypes of IL-12B.
Comparison of results of HD patients that developed
anti-HBs as a result of HBV vaccination or infection
(subgroups Ib and IIb)
Comparison of subgroups Ib and IIb in respect to the IL-
12A and IL-12B polymorphic variants showed that patients
Table 5 The selected demographic, clinical and laboratory data of infected hemodialysis patients divided into subgroups IIa and IIb with
comparison of results to those of vaccinated patients (subgroups Ia and Ib)












Subgroup IIa Subgroup IIb
(n = 55) (n = 182)
Men, n (% of all) 35 (63.6) 101 (55.5) 0.351 0.128 0.857
Age, years 59.3 (19.3–87.7) 61.7 (18.9–90.4) 0.143 <0.001 0.691
RRT duration, years 3.6 (0.1–24.2) 2.5 (0.05–26.0) 0.086 <0.001 0.179
Diabetic nephropathy, n (% of all) 9 (16.4) 53 (29.1) 0.079 0.005 0.363
Chronic glomerulonephritis, n (% of all) 17 (30.9) 30 (16.5) 0.032 <0.001 0.423
Hypertensive nephropathy, n (% of all) 5 (9.1) 24 (13.2) 0.490 0.072 0.326
Chronic tubulointerstitial nephritis, n (% of all) 6 (10.9) 18 (9.9) 0.802 0.613 0.643
History of acute hepatitis B, n (% of all) 5 (9.1) 10 (5.5) 0.568 NA NA
Positive HBsAg, n (% of all) 20a (36.4) 4b (2.2) <0.001 NA NA
Positive HBV DNA, n (% of all) 18 (32.7) 4 (2.2) <0.001 NA NA
Positive anti-HBc, n (% of all) 55 (100 %) 182 (100 %) NA NA NA
Isolated positive anti-HBc, n (% of all anti-HBc positive) 35 (63.6) – NA NA NA
An anti-HBs titre [10 IU/L – 182 (100 %) NA NA 1.000
Positive anti-HCV, n (% of all) 13 (23.6) 37 (20.3) 0.577 <0.001 <0.001
Positive HCV RNA n (% of all anti-HCV positive) 8 (61.5) 24 (64.9) 1.000 0.682 1.000
ALT (IU/L) 18 (4–53) 14 (0–195) 0.295 0.011 0.372
AST (IU/L) 16 (8–81) 16 (1–152) 0.224 0.024 0.389
GGT (IU/L) 23 (–7284) 25 (0–692) 0.762 0.915 0.958
Continuous variables are expressed as median and range. Significant results are indicated using bold font
ALT alanine aminotransferase, anti-HBc antibodies to core antigen of hepatitis B virus, anti-HBs antibodies to surface antigen of hepatitis B
virus, anti-HCV antibodies to hepatitis C virus, AST aspartate aminotransferase, GGT gamma-glutamyltranspeptidase, HBV hepatitis B virus,
HBsAg surface antigen of hepatitis B virus, HBV DNA deoxyribonucleic acid of hepatitis B virus, HCV RNA ribonucleic acid of hepatitis C virus,
NA not applicable, RRT renal replacement therapy
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who developed anti-HBs in response to hepatitis B vacci-
nation showed higher frequencies of GA rs568408 IL-12A
(adjusted OR 2.4, 95 % CI 1.2–4.9, P = 0.015) and GA/
AA (adjusted OR 2.5, 95 % CI 1.3–5.0, P = 0.007), and a
lower frequency of GG rs568408 IL-12A (adjusted OR 0.4,
95 % CI 0.2–0.8, P = 0.007) compared to any other
examined genotypes of IL-12A.
Discussion
Gene polymorphisms of many cytokines have been estab-
lished independently as being associated with a response to
inoculation with the hepatitis B vaccine [25, 33–36] or with
HBV clearance after natural infection [24, 37–42]. Our
study suggests that cytokine gene polymorphisms associ-
ated with a positive anti-HBs phenotype may be different
in the case of vaccination than those shown in the case of
HBV infection.
IL-12 polymorphism in vaccinated HD patients
The presence of deficient Th1-like cells is mentioned
among the causes of non-responsiveness to hepatitis B
vaccination [43–45]. IL-12 is a Th1 response agonist.
Peripheral blood mononuclear cells from high responders
to HBV vaccines show an elevated production of IL-2, IL-
12, and interferon (IFN)-gamma [45, 46]. In dialysis
patients, however, the deficit of IFN-gamma has been
noted, despite increased levels of serum IL-12 [47] or
plasma free IL-18 [48]. These findings suggest the impor-
tance of proper genetic regulation of cytokine production
and function in uremic patients.
In this study, multiple statistical analyses, with included
a calculation of OR with 95 % CI, adjustment for possible
confounding variables and logistic regression analysis,
indicated that GA rs568408 IL-12A may be the probable
polymorphic variant individually associated with anti-HBs
development in vaccinated HD patients. An application of
the Bonferroni correction for multiple testing showed,
however, that the association of GA IL-12A with the anti-
HBs phenotype is too weak to be significant after correc-
tion. Although the Bonferroni correction is widely used,
there is a criticism to this method [49] and not all authors
Table 6 IL-12 polymorphisms
in hemodialysis non-responders
to hepatitis B virus (HBV)
transmission (subgroup IIa) and
hemodialysis responders to
HBV transmission (subgroup
IIb) with the development of
antibodies to surface antigen of
HBV
a Odds ratio (OR) after
adjustment for HBV surface
antigen and chronic
glomerulonephritis as a cause of
renal replacement therapy









(n = 55) n (%)
Subgroup IIb
(n = 182) n (%)
OR (95 % CI) P value
IL-12A
GG 34 (61.8) 130 (71.4) Referent
GA 17 (30.9) 48 (26.4) 1.0 (0.4–2.2)a 0.954
AA 4 (7.3) 4 (2.2) 0.6 (0.2–1.3)a 0.182
GA/AA 21 (38.2) 52 (28.6) 0.8 (0.4–1.8)a 0.660
AA 4 (7.3) 4 (2.2) Referent
GA/GG 51 (92.7) 178 (97.3) 3.1 (0.6–16.4)a 0.177
Allele G 85 (77.3) 308 (84.6) Referent
Allele A 25 (22.7) 56 (15.4) 0.62 (0.4–1.0) 0.083
IL-12B
AA 39 (70.9) 107 (58.8) Referent
AC 9 (16.4) 71 (39.0) 5.7 (1.9–17.2)a 0.002b
CC 7 (12.7) 4 (2.2) 0.2 (0.06–0.8) 0.015b
AC/CC 16 (29.1) 75 (41.2) 2.7 (1.1–6.2)a 0.022c
CC 7 (12.7) 4 (2.2) Referent
AC/AA 48 (87.3) 178 (97.8) 7.0 (1.7–28.7)a 0.006
Allele A 87 (79.1) 285 (78.3) Referent
Allele C 23 (20.9) 79 (21.7) 1.0 (0.6–1.8) 0.896
Table 7 Selected dichotomized effects of the IL-12A rs568408 and










All other genotypes 48 (87.3) 129 (70.9) Referent
rs568408 GG and
rs3212227 AC
7 (12.7) 53 (29.1) 4.0
(1.3–11.9)a
0.012
All other genotypes 53 (96.4) 181 (99.5) Referent
rs568408 GG and
rs3212227 CC
2 (3.6) 1 (0.5) 0.2
(0.03–0.8)a
0.025
All other genotypes 53 (96.4) 181 (99.5) Referent
rs568408 AA and
rs3212227 AA
2 (3.6) 1 (0.5) 0.09
(0.008–1.0)a
0.049
a Odds ratio (OR) after adjustment for HBV surface antigen and chronic
glomerulonephritis as a cause of renal replacement therapy
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are willing to use it in genetic studies [25]. Further studies
with the inclusion of more patients may reach a statistical
significance with the Bonferroni correction and may elu-
cidate the significance of the association between rs568408
IL-12A and a response to the hepatitis B vaccine. To our
knowledge, we took the first step in this analysis.
In 2004, the IL-12B promoter S allele was associated
with the non-responsiveness to hepatitis B vaccination,
whereas the promoter L allele, 30 UTR A and 30 UTR C
were not associated with the responder/non-responder
phenotype. The heterozygosity of the IL-12B promoter was
a significant contributor to the non-responder phenotype
[25]. In our study IL-12B rs3212227 30UTR A[C was not
individually associated with the responder/non-responder
phenotype after hepatitis B vaccination.
It is worth mentioning that HD patients frequently
exhibit a deteriorated clinical status due to uremic, dial-
ysis-related, and incidental complications. Hepatitis B
vaccination is being performed (and repeated as needed)
in the most optimal clinical status of each individual HD
patient. Moreover, if the clinical status of a hepatitis B
vaccine non-responder improves significantly, a booster
dose is given by many clinicians, despite a previous full
vaccination series in these patients. This practice may
explain why the positive anti-HBs phenotype is associated
with longer RRT vintage [50, this study]. Additionally,
hepatitis B vaccine responders were younger and the
prevalence of diabetic nephropathy was less frequent in
this group, whereas chronic glomerulonephritis as a cause
of RRT was more frequent. Patients dialyzed due to pri-
mary renal disease are usually in much better general
condition than patients suffering from multi-organ dis-
eases, such as diabetes mellitus. Older age, shorter RRT
vintage, and diabetes mellitus are well-known risk factors
associated with non-responsiveness to hepatitis B vacci-
nation [50–52]. To decrease the impact of confounding
variables on the results of genotype distribution analysis,
OR were adjusted for age, RRT vintage, and the main
causes of RRT. There were no differences in gender
distribution between responders and non-responders, as
shown in previous studies [53, 54]. Infection with HCV
was also documented as a probable cause of hepatitis B
vaccination failure [55], but in this study we did not
observe a significant influence of HCV infection on anti-
HBs development, because patients were established as
responders or non-responders prior to HCV infection.
Furthermore, it has been shown that HCV patients secrete
normal amounts of IL-12 [46].
Theoretically, genetic investigations could help in the
development of improved hepatitis B vaccines that may
eventually reduce the proportion of vaccine failures [56].
The use of exogenous IL-12 as an adjuvant to augment
anti-HBs development in response to hepatitis B vaccines
has previously been discussed [46, 57]. Our data do not
provide clear confirmatory evidence that such an action at
the genetic level could be evidently helpful in the case of
IL-12 polymorphic variants.
Table 8 Selected combined effects of the IL-12A rs568408 and IL-






































2 (3.6) 1 (0.5) 0.5 (0.3–0.8)a 0.009c
a Odds ratio (OR) after adjustment for HBV surface antigen and
chronic glomerulonephritis as a cause of renal replacement therapy
b Significant after the Bonferroni correction for multiple comparisons
(P \ 0.006)
c Non-significant after the Bonferroni correction for multiple com-
parisons (P [ 0.006)
Table 9 Statistical evidence for association of IL-12B polymorphism
with anti-HBs development in response to hepatitis B virus infection
IL-12B
polymorphism












95 % CI, P)


















na not applicable, ns non-significant
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IL-12 polymorphism in infected HD patients
An increase of serum IL-12 level was associated with more
effective HBV DNA clearance in patients with chronic
hepatitis B [58], but no association with HBV persistence
and IL-12A exon 7 ?6400 C[T, ?6624 G[A, 30UTR
?7003 T[C SNPs and haplotype of IL-12A ?6400/?6624/
?7003 was shown in the study by Park et al. [24]. In our
study, the IL-12A rs568408 30UTR G[A was not individ-
ually associated with anti-HBs development after HBV
transmission. Therefore, the IL-12A polymorphism seems
not to be involved in HBV elimination and development of
protective anti-HBs. Different results were shown in the
case of the IL-12B rs3212227 30UTR A[C: the AC geno-
type of IL-12B was associated with a positive anti-HBs
phenotype after HBV infection in HD patients. Individuals
heterozygous in TaqI RFLP at position 1188 in the 30URT
of the IL-12B p40 gene (rs3212227) showed intermediate
secretion of IL-12 p70 after stimulation of monocytes with
Staphylococcus aureus strain Cowan and IFN-gamma
compared to homozygous individuals [23]. Dichotomized
and combined effects of IL-12A and IL-12B genotypes
confirm that IL-12B polymorphic variants have priority in
the determination of anti-HBs phenotype in HBV infected
HD patients.
The deviation of rs3212227 IL-12B polymorphic
variants from Hardy–Weinberg equilibrium in HBV
infected HD patients of subgroup IIa needs to be dis-
cussed. The IL-12B polymorphism was consistent with
Hardy–Weinberg equilibrium in subgroup IIb and con-
trols. This may suggest that significant differences in the
characteristics of subgroups IIa and IIb could be involved
in the observed discrepancy. As expected from the nat-
ural course of HBV infection, anti-HBc positive patients
that did not develop anti-HBs are more frequently
HBsAg/HBV DNA positive compared to patients with
developed protective anti-HBs. The coexistence of posi-
tive HBsAg and anti-HBs was described for 9–21 % of
chronic HBV carriers [59, 60]. In our study, this coex-
istence occurred in about 17 %. Subgroup IIa included
also a higher percentage of patients with chronic glo-
merulonephritis compared to subgroup IIb. As already
mentioned, the former group also showed a higher
prevalence of persistent HBV infection as indicated by
the positive HBV DNA tests. Glomerulonephritis is an
important extrahepatic manifestation of chronic HBV
infection [61], and this etiology was probable also in the
examined HBV DNA positive patients, especially con-
sidering that in the Wielkopolska region of Poland the
majority (82.1 %) of HBsAg positive HD patients
underwent HBV infection prior to dialysis commence-
ment [62]. Therefore, these factors (HBsAg/HBV DNA
positivity, chronic glomerulonephritis prevalence) are
closely related to the type of manifestation of HBV
infection, and the heterogeneity of both subgroups in this
respect is a consequence of patients’ categorization as
anti-HBs positive or negative. Interestingly, significant
gender differences did not occur between HBV infected
patients with either the positive or negative anti-HBs
phenotype. In most human populations, women are more
likely than men to produce anti-HBs in response to HBV
vaccination [63]. HBV infected women receiving dialysis
treatment also developed anti-HBs more frequently than
men [64]. Isolated anti-HBc positivity seems not to be
gender-dependent [65, 66]. HBV infected HD patients
without developed anti-HBs (subgroup IIa) had predom-
inantly isolated anti-HBc positivity (63.6 %), therefore
the higher prevalence of men (63.6 %) in this group did
not reach significance in comparison with men that
developed anti-HBs (55.5 %, subgroup IIb).
Additionally, subgroup IIa was small, because the
selection criteria for inclusion into it were very specific.
Until the year 2009 in Poland, when the results of anti-HBc
testing were predominantly not known, HBsAg negative/
anti-HBc positive patients were hepatitis B vaccinated
using a standard procedure. Because patients with isolated
anti-HBc positivity may develop anti-HBs in some cases in
response to vaccination [67, 68], we have qualified to
group II only patients who were not vaccinated to be sure
that the immune response is affected only by natural
infection and not vaccination. Moreover, to find individuals
who are not vaccinated for HBV will become more difficult
each year in Poland, because all newborns are vaccinated
on a mandatory basis. On the other hand, sample power
frequently exceeded 80 % in comparisons between sub-
groups IIa and IIb in respect to the rs3212227 IL-12B
polymorphic variants. All of these facts may suggest that
the lack of agreement with Hardy–Weinberg equilibrium
has to be considered as a true difference between the
examined groups.
Conclusions
1. IL-12A and IL-12B polymorphic variants are associ-
ated in Caucasian HD patients with the anti-HBs
phenotype.
2. The GA rs568408 IL-12A variant seems to be predic-
tive for the development of protective immunization in
response to hepatitis B vaccination in HD patients.
3. The AC rs3212227 IL-12B polymorphism is a predic-
tor of favorable outcome after HBV infection in HD
patients. HD patients that do not develop anti-HBs
after HBV infection (HBsAg carriers or individuals
with isolated anti-HBc serum profile) more frequently
bear the CC rs3212227 IL-12B (12.7 % vs 2.2 %)
6908 Mol Biol Rep (2013) 40:6899–6911
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polymorphic variant than patients with HBV-induced
anti-HBs development.
Acknowledgments We would like to express our gratitude to
physicians of the dialysis centers for their help in collecting the
participants’ data and consent during the study period. We would also
like to thank Dr. Margarita Lianeri for her assistance.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
References
1. Morbidity and Mortality Weekly Report (2001) Recommenda-
tions for preventing transmission of infections among chronic
hemodialysis patients. US Department of Health and Human
Services. Centers Dis Control Prev 50:RR-5
2. Nahar K, Jahan M, Nessa A, Tabassum S (2011) Antibody
responses after hepatitis B vaccination among maintenance hae-
modialysis patients. Bangladesh Med Res Counc Bull 37:88–91
3. Idrees MK, Batool S, Ahmed E (2011) Hepatitis B virus among
maintainence haemodialysis patients: a report from Karachi,
Pakistan. J Pak Med Assoc 61:1210–1214
4. Ferreira RC, Teles SA, Dias MA, Tavares VR, Silva SA, Gomes
SA et al (2006) Hepatitis B virus infection profile in hemodialysis
patients in Central Brazil: prevalence, risk factors, and genotypes.
Mem Inst Oswaldo Cruz 101:689–692. doi:10.1590/S0074-
02762006000600019
5. Cabrerizo M, Bartolome´ J, De Sequera P, Caramelo C, Carren´o V
(1997) Hepatitis B virus DNA in serum and blood cells of hepatitis
B surface antigen-negative hemodialysis patients and staff. J Am
Soc Nephrol 8:1443–1447. doi:1046-6673/0809-1443$03.00/0
6. Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M
et al (2008) Association between hepatitis B virus and pancreatic
cancer. J Clin Oncol 26:4557–4562. doi:10.1200/JCO.2008.17.
3526
7. Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Sai-
genji K (2008) Impact of occult hepatitis B virus infection and
prior hepatitis B virus infection on development of hepatocellular
carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Scand J Gastroenterol 43:849–856
8. Kim MJ, Kwon OS, Chung NS, Lee SY, Jung HS, Park DK et al
(2008) The significance of anti-HBc and occult hepatitis B virus
infection in the occurrence of hepatocellular carcinoma in
patients with HBsAg and anti-HCV negative alcoholic cirrhosis
[article in Korean]. Korean J Hepatol 14:67–76. doi:10.3350/
kjhep.2008.14.1.67
9. Cendoroglo Neto M, Draibe SA, Silva AE, Ferraz ML, Granato
C, Pereira CA et al (1995) Incidence of and risk factors for
hepatitis B virus and hepatitis C virus infection among hae-
modialysis and CAPD patients: evidence for environmental
transmission. Nephrol Dial Transplant 10:240–246 not applicable
10. Grzegorzewska AE, Kaczmarek-Leki V, Młot-Michalska M,
Niepolski L (2011) Seroconversion rate to positivity for anti-
bodies against core antigen of hepatitis B virus and duration of
renal replacement therapy. Nephrol Dial Transplant 26:970–976.
doi:10.1093/ndt/gfq499
11. Grzegorzewska AE, Kurzawska-Firlej D, Ratajewski W, Frank-
iewicz D, Niepolski L, Kaczmarek A (2010) Antibodies to core
antigen of hepatitis B virus in patients on renal replacement
therapy: association with demographic, clinical and laboratory
data. Nephron Clin Pract 114:c194–c203. doi:10.1159/00026
2302
12. Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P,
Gilson R et al (2008) Hepatitis B virus e antigen loss during
adefovir dipivoxil therapy is associated with enhanced virus-
specific CD4? T-cell reactivity. Antimicrob Agents Chemother
52:312–320. doi:10.1128/AAC.00467-07
13. Wu JF, Wu TC, Chen CH, Ni YH, Chen HL, Hsu HY et al (2010)
Serum levels of interleukin-10 and interleukin-12 predict early,
spontaneous hepatitis B virus e antigen seroconversion. Gastro-
enterology 138:165–172. doi:10.1053/j.gastro.2009.09.018
14. Rossol S, Marinos G, Carucci P, Singer MV, Roger W, Naoumov
NV (1997) Interleukin-12 induction of Th1 cytokines is important
for viral clearance in chronic hepatitis B. J Clin Invest
99:3025–3033. doi:10.1172/JCI119498
15. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT et al
(1998) Development of Th1 and Th2 populations and the nature
of immune responses to hepatitis B virus DNA vaccines can be
modulated by codelivery of various cytokine genes. J Immunol
160:1320–1329 0022-1767/98/$02.00
16. Schirmbeck R, Reimann J (2001) Modulation of gene-gun-med-
iated Th2 immunity to hepatitis B surface antigen by bacterial
CpG motifs or IL-12. Intervirology 44:115–123
17. Kalechman Y, Gafter U, Sobelman D, Sredni B (1990) The effect
of a single whole-blood transfusion on cytokine secretion. J Clin
Immunol 10:99–105
18. Shaashua L, Sominsky L, Levi B, Sorski L, Reznick M, Page GG
et al (2012) In vivo suppression of plasma IL-12 levels by acute
and chronic stress paradigms: potential mediating mechanisms
and sex differences. Brain Behav Immun 26:996–1005. doi:10.
1016/j.bbi.2012.05.012
19. Kuvibidila S, Warrier RP (2004) Differential effects of iron
deficiency and underfeeding on serum levels of interleukin-10,
interleukin-12p40, and interferon-gamma in mice. Cytokine
26:73–81
20. Grzybowska EA, Wilczynska A, Siedlecki JA (2001) Regulatory
functions of 30UTRs. Biochem Biophys Res Commun
288:291–295. doi:10.1006/bbrc.2001.5738
21. Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J et al (2009)
Interactions of IL-12A and IL-12B polymorphisms on the risk of
cervical cancer in Chinese women. Clin Cancer Res 15:400–405.
doi:10.1158/1078-0432.CCR-08-1829
22. Zwiers A, Seegers D, Heijmans R, Koch A, Hampe J, Nikolaus S
et al (2004) Definition of polymorphisms and haplotypes in the
interleukin-12B gene: association with IL-12 production but not
with Crohn’s disease. Genes Immun 5:675–677. doi:10.1038/sj.
gene.6364131
23. Seegers D, Zwiers A, Strober W, Pen˜a AS, Bouma G (2002) A
TaqI polymorphism in the 30UTR of the IL-12 p40 gene corre-
lates with increased IL-12 secretion. Genes Immun 3:419–423.
doi:10.1038/sj.gene.6363919
24. Park JS, Cheong JY, Kang JK, Cho JH, Yu S, Shin HD et al
(2007) Association of interleukin-12 gene polymorphism with
persistence of hepatitis B virus infection and hepatocellular
carcinoma [article in Korean]. Korean J Gastroenterol 50:
313–318
25. Wang C, Tang J, Song W, Lobashevsky E, Wilson CM, Kaslow
RA (2004) HLA and cytokine gene polymorphisms are inde-
pendently associated with responses to hepatitis B vaccination.
Hepatology 39:978–988. doi:10.1002/hep.20142
26. Grzegorzewska AE, Wobszal P, Jagodzin´ski PP (2012) Inter-
leukin-18 promoter polymorphism and development of anti-
bodies to surface antigen of hepatitis B virus in hemodialysis
patients. Kidney Blood Press Res 35:1–8. doi:10.1159/0003
29932
Mol Biol Rep (2013) 40:6899–6911 6909
123
27. Grzegorzewska AE, Wobszal PM, Mostowska A, Jagodzin´ski PP
(2012) Antibodies to hepatitis B virus surface antigen and
interleukin 12 and interleukin 18 gene polymorphisms in he-
modialysis patients. BMC Nephrol. doi:10.1186/1471-2369-13-
75
28. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB
(1986) Immune response to the pre-S(1) region of the hepatitis B
surface antigen (HBsAg): a pre-S(1)-specific T cell response can
bypass nonresponsiveness to the pre-S(2) and S regions of
HBsAg. J Immunol 137:315–322
29. Yap I, Guan R, Chan SH (1992) Recombinant DNA hepatitis B
vaccine containing Pre-S components of the HBV coat protein–a
preliminary study on immunogenicity. Vaccine 10:439–442
30. European Best Practice Guidelines (2002) Prevention and man-
agement of HBV, HCV and HIV in HD patients. Nephrol Dial
Transplant 17(suppl.7):78–87. doi:10.1093/ndt/17.suppl_7.73
31. Zała˛czniki do rozporza˛dzenia Ministra Zdrowia z dnia 18 kwi-
etnia 2005 r.
32. Hahn LW, Ritchie MD, Moore JH (2003) Multifactor dimen-
sionality reduction software for detecting gene–gene and gene-
environment interactions. Bioinformatics 19:376–382
33. Chen J, Liang Z, Lu F, Fang X, Liu S, Zeng Y et al (2011) Toll-
like receptors and cytokines/cytokine receptors polymorphisms
associate with non-response to hepatitis B vaccine. Vaccine
29:706–711. doi:10.1016/j.vaccine.2010.11.023
34. Yucesoy B, Sleijffers A, Kashon M, Garssen J, de Gruijl FR,
Boland GJ et al (2002) IL-1b gene polymorphisms influence
hepatitis B vaccination. Vaccine 20:3193–3196
35. Ho¨hler T, Reuss E, Freitag CM, Schneider PM (2005) A func-
tional polymorphism in the IL-10 promoter influences the
response after vaccination with HBsAg and hepatitis A. Hepa-
tology 42:72–76
36. Sleijffers A, Yucesoy B, Kashon M, Garssen J, De Gruijl FR, Bo-
land GJ et al (2003) Cytokine polymorphisms play a role in sus-
ceptibility to ultraviolet B-induced modulation of immune
responses after hepatitis B vaccination. J Immunol 170:3423–3428.
doi:0022-1767/03/$02.00
37. Cheong JY, Cho SW, Oh B, Kimm K, Lee KM, Shin SJ et al
(2010) Association of interleukin-18 gene polymorphisms with
hepatitis B virus clearance. Dig Dis Sci 55:1113–1119. doi:10.
1007/s10620-009-0819-z
38. Li W, Jiang Y, Jin Q, Shi X, Jin J, Gao Y et al (2011) Expression
and gene polymorphisms of interleukin 28B and hepatitis B virus
infection in a Chinese Han population. Liver Int 31:1118–1126.
doi:10.1111/j.1478-3231.2011.02507
39. Xia Q, Zhou L, Liu D, Chen Z, Chen F (2011) Relationship
between TNF- \alpha[ gene promoter polymorphisms and out-
comes of hepatitis B virus infections: a meta-analysis. PLoS One
6:e19606. doi:10.1371/journal.pone.0019606
40. Zhang TC, Pan FM, Zhang LZ, Gao YF, Zhang ZH, Gao J et al
(2011) A meta-analysis of the relation of polymorphism at sites -
1082 and -592 of the IL-10 gene promoter with susceptibility and
clearance to persistent hepatitis B virus infection in the Chinese
population. Infection 39:21–37
41. Shin HD, Park BL, Cheong HS, Yoon JH, Kim YJ, Lee HS (2007)
SPP1 polymorphisms associated with HBV clearance and HCC
occurrence. Int J Epidemiol 36:1001–1008. doi:10.1093/ije/
dym093
42. Li Y, Shi Y, Chen J, Cai B, Ying B, Wang L (2012) Association
of polymorphisms in interleukin-18 and interleukin-28B with
hepatitis B recurrence after liver transplantation in Chinese Han
population. Int J Immunogenet 39:346–352. doi:10.1111/j.1744-
313X.2012.01097
43. Chedid MG, Deulofeut H, Yunis DE, Lara-Marquez ML, Salazar
M, Deulofeut R et al (1997) Defect in Th1-like cells of nonre-
sponders to hepatitis B vaccine. Hum Immunol 58:42–51
44. Kardar GA, Jeddi-Tehrani M, Shokri F (2002) Diminished Th1
and Th2 cytokine production in healthy adult nonresponders to
recombinant hepatitis B vaccine. Scand J Immunol 55:311–314
45. Vingerhoets J, Vanham G, Kestens L, Penne G, Leroux-Roels G,
Gigase P (1994) Deficient T-cell responses in non-responders to
hepatitis B vaccination: absence of TH1 cytokine production.
Immunol Lett 39:163–168
46. Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, Daly K
et al (1999) Altered helper T lymphocyte function associated with
chronic hepatitis B virus infection and its role in response to
therapeutic vaccination in humans. J Immunol 162:3088–3095.
doi:0022-1767/99/$02.00
47. Ishizuka T, Nitta K, Yokoyama T, Hayashi T, Futatsuyama K,
Kimata N et al (2002) Increased serum levels of interleukin-12 may
be associated with Th1 differentiation in hemodialysis patients.
Nephron 90:503–504. doi:0028-2766/02/0904-0503$18.50/0
48. Lonnemann G, Novick D, Rubinstein M, Dinarello CA (2003)
Interleukin-18, interleukin-18 binding protein and impaired pro-
duction of interferon-gamma in chronic renal failure. Clin
Nephrol 60:327–334
49. Nakagawa S (2004) A farewell to Bonferroni: the problems of
low statistical power and publication bias. Behav Ecol
15:1044–1045. doi:10.1093/beheco/arh107
50. Fabrizi F, Di Filippo S, Marcelli D, Guarnori I, Raffaele L,
Crepaldi M et al (1996) Recombinant hepatitis B vaccine use in
chronic hemodialysis patients. Long-term evaluation and cost-
effectiveness analysis. Nephron 72:536–543 0028-2766/96/0724-
0536$10.00/0
51. Shatat HZ, Kotkat AM, Farghaly AG (2000) Immune response to
hepatitis B vaccine in haemodialysis patients. J Egypt Public
Health Assoc 75:257–2575
52. Alavian SM, Tabatabaei SV (2010) The effect of diabetes mel-
litus on immunological response to hepatitis B virus vaccine in
individuals with chronic kidney disease: a meta-analysis of cur-
rent literature. Vaccine 28:3773–3777. doi:10.1016/j.vaccine.
2010.03.038
53. Douvin C, Simon D, Charles MA, Deforges L, Bierling P, Lehner
V et al (1997) Hepatitis B vaccination in diabetic patients.
Randomized trial comparing recombinant vaccines containing
and not containing pre-S2 antigen. Diabetes Care 20:148–151
54. Cockcroft A, Soper P, Insall C, Kennard Y, Chapman S, Gooch C
et al (1990) Antibody response after hepatitis B immunisation in
a group of health care workers. Br J Ind Med 47:199–202
55. Navarro JF, Teruel JL, Mateos ML, Marcen R, Ortuno J (1996)
Antibody level after hepatitis B vaccination in hemodialysis patients:
influence of hepatitis C virus infection. Am J Nephrol 16:95–97
56. Hennig BJ, Fielding K, Broxholme J, Diatta M, Mendy M, Moore
C et al (2008) Host genetic factors and vaccine-induced immunity
to hepatitis B virus infection. PLoS One 3:e1898. doi:10.1371/
journal.pone.0001898
57. Du DW, Jia ZS, Li GY, Zhou YY (2003) HBV DNA vaccine with
adjuvant cytokines induced specific immune responses against
HBV infection. World J Gastroenterol 9:108–111
58. Zeuzem S, Carren˜o V (2001) Interleukin-12 in the treatment of
chronic hepatitis B and C. Antiviral Res 52:181–188 PII: S0166-
3542(01)00183-8
59. Lada O, Benhamou Y, Poynard T, Thibault V (2006) Coexistence
of hepatitis B surface antigen (HBs Ag) and Anti-HBs antibodies
in chronic hepatitis B virus carriers: influence of ‘‘a’’ determinant
variants. J Virol March 80:2968–2975. doi:10.1128/JVI.80.6.
2968-2975.2006
60. Kohno H, Inoue T, Tsuda F, Okamoto H, Akahane Y (1996)
Mutations in the envelope gene of hepatitis B virus variants co-
occurring with antibody to surface antigen in sera from patients
with chronic hepatitis B. J Gen Virol 77:1825–1831. doi:10.1099/
0022-1317-77-8-1825
6910 Mol Biol Rep (2013) 40:6899–6911
123
61. Chan TM (2010) Hepatitis B and renal disease. Curr Hepat Rep
9:99–105. doi:10.1007/s11901-010-0042-6
62. Grzegorzewska AE, Kurzawska-Firlej D, S´widerski A, de Mezer-
Dambek M, Frankiewicz D, Zaremba-Drobnik D et al (2008)
Infections with hepatitis B virus in hemodialysis units of Wie-
lkopolska. Przegl Epidemiol 62:29–37
63. Blumberg BS (1979) Sex differences in response to hepatitis B
virus I History. Arthritis Rheum 22:1261–1266
64. London WT, Drew JS (2013) Sex differences in response to
hepatitis B infection among patients receiving chronic dialysis
treatment. HIV Clin Trials 14:17–20
65. Karaosmanoglu HK, Aydin OA, Nazlican O (2011) Isolated anti-
HBc among HIV-infected patients in Istanbul, Turkey. Vaccine
29:1721–1726. doi:10.1016/j.vaccine.2010.11.044
66. Sun HY, Lee HC, Liu CE, Yang CL, Su SC, Ko WC et al (2010)
Factors associated with isolated anti-hepatitis B core antibody in
HIV-positive patients: impact of compromised immunity. J Viral
Hepat 17:578–587
67. Tsouchnikas I, Dounousi E, Xanthopoulou K, Papakonstantinou
S, Thomoglou V, Tsakiris D (2007) Loss of hepatitis B immunity
in hemodialysis patients acquired either naturally or after vacci-
nation. Clin Nephrol 68:228–234
68. Barałkiewicz G, Juszczyk J, Grzegorzewska A, Czarnecki R
(1996) The results of the vaccination against hepatitis B (‘En-
gerix B’) in dialysed uaemic patients [article in Polish]. Hepat-
ologia Pol 3:11–14
Mol Biol Rep (2013) 40:6899–6911 6911
123
